Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Academic Funding, GSK Looks to Zap Life Into Electroceuticals

This article was originally published in The Pink Sheet Daily

Executive Summary

By seeding exploratory lab work across several biomedical and engineering disciplines, GlaxoSmithKline wants to understand how neural signals regulate diseases and eventually to design devices that can alter signals and provide therapeutic benefit.

You may also be interested in...



GSK Ventures Into The Device World Through Bioelectronic Investment

The British pharma has financed a new venture fund to create a presence in an emerging technology and help jump-start the fledgling industry because it believes that the science has reached a transition point.

Deals of the Week: Ante Up For Antisense, Pharma Places Another Isis Bet

The biotech brings Roche on as its seventh biopharma partner, building on the more than $5 billion in potential partnership revenue the biotech had already amassed. If all goes as planned, Isis will add five marketed products within the next five years to the newly approved Kynamro. But Wall Street doesn’t expect Isis’ revenues to increase much anytime soon. Plus more notable deals this week…

Neuromodulation Market: Innovation Brings High-Growth Rewards

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel